Stellaromics Secures Funding
Summary
Stellaromics, a pioneer in 3D spatial biology spun out of the laboratories of Karl Deisseroth and Xiao Wang, today announced the completion of a Series B funding round in the amount of $80M. These breakthroughs, based on the companys STARmap and RIBOmap technologies, greatly expand upon applications of traditional 2D methods by offering a true 3D perspective, providing researchers with a deeper understanding of tissue organization, cellular interactions, and disease mechanisms. The emergence of 3D spatial technology marks a transformative step toward creating comprehensive disease atlases, paving the way for more precise diagnostics and targeted therapies to improve patient care. Stellaromics will showcase the Pyxa technology at the AGBT 2025 conference in Marco Island, Florida from February 23rd-26th.Stellaromics is a privately held company dedicated to pioneering breakthroughs in 3D spatial multi-omics. The companys mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health.